Sorrento’s R&D is focused on driving innovation in COVID-19, cancer treatment, full pain control and autoimmune diseases

Portfolio	Key Programs	Indication	Preclinical	Phase I	Phase II	Phase III/Pivotal	FDA Approval
COVID-19 Programs	COVI-TRACE™ (diagnostic) Diagnostic Test 0%* FDA Emergency Use Authorization (EUA) Application Expected COVI-STIX™ (diagnostic) Antigen Test 0%* FDA Emergency Use Authorization (EUA) Application Submitted COVI-TRACK™ – Platinum (diagnostic) Next Generation Antibody Test 0%* In final manufacturing and clinical testing COVI-GUARD™ (treatment) Neutralizing Antibody (IV) in Inpatients 30%* COVI-AMG™ (treatment) Neutralizing Antibody (IV) in Outpatients 30%* COVI-DROPS™ (treatment) Neutralizing Antibody (Intranasal) in Outpatients 10%* COVI-SHIELD™ (treatment) Neutralizing Abs (IV) in Inpatients 10%* COVIDTRAP™ (treatment) ACE2 Receptor Decoy (IV) in Inpatients 10%* ABIVERTINIB (treatment) Severe or Critical COVID-19 in ICU Patients 55%* SALICYN – 30 (treatment) Anti-viral 10%* COVI-MSC (treatment) ARDS due to COVID-19 in ICU Pts 30%*
Immunotherapy	CD38 CAR-T Multiple Myeloma 30%* CD38 DAR-T Multiple Myeloma 10%* CD38 ADC Amyloidosis 30%* Seprehvir™ Solid Tumors 30%* Seprehvec™ Solid Tumors 30%* ABIVERTINIB NSCLC 80%* ADNIC Solid and Liquid Tumors 55%*
Pain	RTX (resiniferatoxin) Epidural route Intractable Pain in Advanced Cancer 55%* Orphan designation RTX (resiniferatoxin) Intra-articular route Moderate to Severe OA 55%*
Lymphatic Delivery	Sofusa® anti-TNF Autoimmune 30%* Sofusa® anti-PD-1 CTCL 30%*

COVID-19 Programs
Key Programs (Indication)	Phase
COVI-TRACE™ (diagnostic) FDA EUA COVI-STIX™ (diagnostic) FDA EUA COVI-TRACK™ – Platinum (diagnostic) FDA EUA COVI-GUARD™ (treatment) Ph I COVI-AMG™ (treatment) Ph I COVI-DROPS™ (treatment) Preclinical COVI-SHIELD™ (treatment) Preclinical COVIDTRAP™ (treatment) Preclinical ABIVERTINIB (treatment) Ph II SALICYN – 30 (treatment) Preclinical COVI-MSC (treatment) Ph I

Immunotherapy
Key Programs (Indication)	Phase
CD38 CAR-T (Multiple Myeloma) Ph I CD38 DAR-T (Multiple Myeloma) Preclinical CD38 ADC (Amyloidosis) Ph I Seprehvir™ (Solid Tumors) Ph I Seprehvec™ (Solid Tumors) Ph I ABIVERTINIB (NSCLC) PhIII/Pivotal ADNIC (Solid and Liquid Tumors) Ph II

Pain
Key Programs (Indication)	Phase
RTX (resiniferatoxin) Epidural route (Terminal Cancer Pain) Ph II RTX (resiniferatoxin) Intra-articular route (Moderate to Severe OA) Ph II

Lymphatic Delivery
Key Programs (Indication)	Phase
Sofusa® anti-TNF (Autoimmune) Ph I Sofusa® anti-PD-1 (Immuno Oncology) Ph I